Jun 10, 2019 / 02:00PM GMT
Presentations and Diabetes Portfolio
Jun 10, 2019 / 02:00PM GMT
=====================
Corporate Participants
=====================
* Brad Woodward
Eli Lilly and Company - Senior Medical Director of Lilly Diabetes & Incretins Platform Team Leader
* Enrique A. Conterno
Eli Lilly and Company - Senior VP & President of Lilly Diabetes and Lilly USA
* Ilya Yuffa
Eli Lilly and Company - VP US Diabetes
* Jeff Emmick
Eli Lilly and Company - VP Diabetes Product Development
* Mike Czapar
Eli Lilly and Company - Investor Relations
=====================
Conference Call Participants
=====================
* Andrew Simon Baum
Citigroup Inc, Research Division - Global Head of Healthcare Research and MD
* Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst
* Damien Conover
Morningstar Inc., Research Division - Sector Director and Equities Strategist
* David Reed Risinger
Morgan Stanley, Research Division - MD in Equity
Eli Lilly and Co
(MIL:1LLY)
€
733.1
-11.4 (-1.53%)
Market Cap: 703.72 Bil
Enterprise Value: 729.10 Bil
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 66/100 Eli Lilly and Co to Discuss ADA Presentations and Diabetes Portfolio Transcript
Jun 10, 2019 / 02:00PM GMT
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot